liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomised trial of a novel hydrocortisone dual-release formulation
Sahlgrenska Academy, University of Gothenburg.
Sahlgrenska Academy, University of Gothenburg.
Sahlgrenska Academy, University of Gothenburg.
Skånes University Hospital, Malmö.
Show others and affiliations
2012 (English)In: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 97, no 2, 473-481 p.Article in journal (Refereed) Published
Abstract [en]

Context: Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile.

Objective: The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets.

Design and Setting: We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers.

Patients: The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM).

Intervention: The same daily dose of hydrocortisone was administered as OD dual-release or TID.

Main Outcome Measure: We evaluated cortisol pharmacokinetics.

Results: Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7 kg, P = 0.005), systolic blood pressure (difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004).

Conclusion: The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM.

Place, publisher, year, edition, pages
The Endocrine Society , 2012. Vol. 97, no 2, 473-481 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-76270DOI: 10.1210/jc.2011-1926ISI: 000301226800043OAI: diva2:513248

funding agencies|DuoCort Pharma AB||Swedish Foundation of Strategic Research||        

Available from: 2012-04-01 Created: 2012-04-01 Last updated: 2014-02-14

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Ekman, BertilWahlberg, Jeanette
By organisation
EndocrinologyFaculty of Health SciencesDepartment of Endocrinology
In the same journal
Journal of Clinical Endocrinology and Metabolism
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 42 hits
ReferencesLink to record
Permanent link

Direct link